SuperworthEmergent BioSolutions market cap EBS
Share price times shares outstanding: what the whole company sells for, since 2011.
- Today, Oct 23, 2026
- $319.4M
- Highest close in our data
- $7.1B
- Aug 2020
Emergent BioSolutions is worth $319.4M at the close on Oct 23, 2026, at $6.23 a share.
That is down 39% over the last year and down 88% over five years.
Its highest close in our data was $7.1B in Aug 2020.
Market cap over time
Year by year
| Year | End of year | Low | High | Change |
|---|---|---|---|---|
| 2026 so far | $319.4M | $235.3M | $680.7M | −51% |
| 2025 | $652.8M | $238.5M | $655.4M | +46% |
| 2024 | $448.1M | $80.9M | $732.1M | +260% |
| 2023 | $124.5M | $103.6M | $812.7M | −79% |
| 2022 | $589.2M | $548.8M | $2.8B | −75% |
| 2021 | $2.3B | $1.8B | $6.6B | −51% |
| 2020 | $4.7B | $2.6B | $7.1B | +70% |
| 2019 | $2.8B | $2.1B | $3.4B | −7% |
| 2018 | $3B | $1.8B | $3.7B | +55% |
| 2017 | $1.9B | $1.2B | $1.9B | +45% |
| 2016 | $1.3B | $1B | $1.8B | −15% |
| 2015 | $1.6B | $1B | $1.6B | +49% |
| 2014 | $1B | $747.7M | $1B | +23% |
| 2013 | $853.9M | $474.2M | $853.9M | +50% |
| 2012 | $567.5M | $476.4M | $656.9M | −6% |
| 2011 | $605.4M | $553.2M | $688.3M | n/a |
Against its peers
Companies in Drug Manufacturers - General nearest Emergent BioSolutions' size, closest first, today.
| Company | Market cap |
|---|---|
| EBSEmergent BioSolutions | $319.4M |
| NATRNatures Sunshine Products | $213.8M |
| ARVNArvinas | $477.3M |
| PBYIPuma Biotechnology | $568.9M |
| IRWDIronwood Pharmaceuticals | $571.7M |
| ZVRAZevra Therapeutics | $582.6M |
| CRMDCorMedix | $611.9M |
| COLLCollegium Pharmaceutical | $747.5M |
| ABUSArbutus Biopharma | $831M |
| AMPHAmphastar Pharmaceuticals | $1.1B |
| OMEROmeros | $1.2B |
| Peer median | $597.2M |
What the market cap tells you
Share price times shares outstanding: what the whole company sells for today.
Size, not quality. Large caps move slower and are covered more. That is all it tells you.
More on Emergent BioSolutions
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.